Isotechnika Receives USAN Approval for Generic Name for Lead Immunosuppressive Drug

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced
today that the Company has received approval from United States
Adopted Name (USAN) for naming of its lead immunosuppressive drug,
ISA247.

The name, voclosporin, is now being reviewed by the International
Nonproprietary Name (INN) expert committee. The INN is scheduled to
publish the proposed list of approved names sometime in mid 2007.
Official notification from the INN would allow Isotechnika to use the
name voclosporin in labelling, publications, and on drug information.
The name will serve to identify the active pharmaceutical substance
during the drugs' life-time worldwide.

ISA247 (voclosporin) is a calcineurin inhibitor, currently being
investigated in a Phase 3 European/Canadian trial for the treatment
of moderate to severe psoriasis and a Phase 2b North American trial
for the prevention of organ rejection in kidney transplant patients
and as a treatment for uveitis in three separate pivotal Phase
2/Phase 3 trials. The latter trial is being coordinated by our
partner, Lux Biosciences.

"Moving toward the name of voclosporin from the previous
nomenclature of ISA247 should assist us in initiating our commercial
branding process. The next step in the naming process is to request
that the USAN approved name, voclosporin, be approved by the
International Nonproprietary Name (INN) Programme of the World Health
Organization (WHO). Pending receipt of this INN approval, ISA247
will, in all future materials, be referred to by its new generic
name, voclosporin," commented Dr. Randall Yatscoff, Isotechnika's
President & CEO.

About Isotechnika

Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world-class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 has successfully completed a
Phase 3 Canadian trial for the treatment of moderate to severe
psoriasis. ISA247 is currently being investigated in a combined Phase
3 European/Canadian psoriasis trial and a Phase 2b North American
trial for the prevention of kidney graft rejection. The Company also
has an additional immunosuppressive compound in its drug pipeline,
TAFA93 which successfully completed Phase 1 clinical trials.

Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can
be found at www.isotechnika.com.

Partnerships with Isotechnika Inc.

Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and commercialize voclosporine for all transplant
indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of voclosporine and TAFA93 specifically with drug eluting devices
for the non-systemic treatment of vascular, cardiovascular, target
vessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive license to develop and commercialize conjugates consisting
of Cellgate's patented transporter technology for the topical
delivery of voclosporine in patients suffering from mild to moderate
psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug, voclosporine for the treatment and prophylaxis of all
ophthalmic diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc.,+1(780)-487-1600-(246), +1(780)-484-4105 (fax),
ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., +1(780)-487-1600-(243),
+1(780)-487-4105 (fax), sgillis-paulgaard@isotechnika.com (ISA.)